» Articles » PMID: 9014602

Relationship Between Disease Severity and Inflammatory Markers in Cystic Fibrosis

Overview
Journal Arch Dis Child
Specialty Pediatrics
Date 1996 Dec 1
PMID 9014602
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the clinical use of measuring neutrophil, lymphocyte, and eosinophil activities, serum myeloperoxidase (MPO), soluble interleukin-2 receptors (sIL-2R), and eosinophil cationic protein (ECP) were measured in 98 patients with cystic fibrosis and in 85 healthy children. Serum concentrations of MPO, sIL-2R, and ECP were increased in patients with cystic fibrosis (median 807 micrograms/l, 4452 pg/ml, 48.8 micrograms/l, respectively) compared with the controls (median 319 micrograms/l, 2743 pg/ml, 9.4 micrograms/l). ECP concentrations, but not serum MPO or sIL-2R, were significantly related to disease severity assessed by the Shwachman-Kulczycki score and by pulmonary function (forced expiratory volume in one second % predicted). Neither ECP nor sIL-2R was influenced by Pseudomonas aeruginosa infection, acute pulmonary exacerbation, or atopy. Serum MPO, however, was strongly correlated with acute pulmonary exacerbation. In the light of these findings the measurement of serum ECP might thus be used for clinical monitoring and for assessing disease severity in cystic fibrosis. The measurement of serum MPO and sIL-2R did not correlate with the disease severity.

Citing Articles

Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Causer A, Shute J, Cummings M, Shepherd A, Gruet M, Costello J Redox Biol. 2020; 32:101436.

PMID: 32044291 PMC: 7264436. DOI: 10.1016/j.redox.2020.101436.


Environmental allergies and respiratory morbidities in cystic fibrosis.

Collaco J, Morrow C, Green D, Cutting G, Mogayzel Jr P Pediatr Pulmonol. 2012; 48(9):857-64.

PMID: 23143815 PMC: 3572264. DOI: 10.1002/ppul.22700.


Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Taylor-Cousar J, Von Kessel K, Young R, Nichols D J Inflamm Res. 2011; 3:61-74.

PMID: 22096358 PMC: 3218732. DOI: 10.2147/jir.s8875.


Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.

Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P Respir Res. 2006; 7:134.

PMID: 17064416 PMC: 1637104. DOI: 10.1186/1465-9921-7-134.


Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Schmitt-Grohe S, Zielen S Paediatr Drugs. 2005; 7(6):353-63.

PMID: 16356023 DOI: 10.2165/00148581-200507060-00004.


References
1.
Olofsson T, Olsson I, Venge P, Elgefors B . Serum myeloperoxidase and lactoferrin in neutropenia. Scand J Haematol. 1977; 18(1):73-80. DOI: 10.1111/j.1600-0609.1977.tb01480.x. View

2.
Mohammed J, Mohammed B, Pawluk L, Bucci D, Baker N, DAVIS W . Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum. J Lab Clin Med. 1988; 112(6):711-20. View

3.
Flavahan N, Slifman N, Gleich G, Vanhoutte P . Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis. 1988; 138(3):685-8. DOI: 10.1164/ajrccm/138.3.685. View

4.
PETERSON C, ENANDER I, Nystrand J, Anderson A, Nilsson L, Venge P . Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy. 1991; 21(5):561-7. DOI: 10.1111/j.1365-2222.1991.tb00847.x. View

5.
Dagli E, Warner J, Besley C, Warner J . Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease. Arch Dis Child. 1992; 67(4):479-81. PMC: 1793340. DOI: 10.1136/adc.67.4.479. View